Scarica l'app Stockscreener
0.3298
6.96%
-0.0223
Precedente Chiudi:
$0.3521
Aprire:
$0.342
Volume 24 ore:
515.92K
Relative Volume:
0.14
Capitalizzazione di mercato:
$4.33M
Reddito:
$1.75M
Utile/perdita netta:
$-5.68M
Rapporto P/E:
-0.0677
EPS:
-4.8726
Flusso di cassa netto:
-
1 W Prestazione:
+5.64%
1M Prestazione:
+15.49%
6M Prestazione:
+38.40%
1 anno Prestazione:
-73.79%
Intervallo 1D:
$0.3259
$0.3571
Intervallo di 1 settimana:
$0.29
$0.375
Portata 52W:
$0.197
$1.79
Scisparc Ltd Stock (SPRC) Company Profile
Confronta SPRC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.339 | 4.33M | 1.75M | -5.68M | 0 | -4.8726 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.19 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.00 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.89 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.26 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.13 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Scisparc Ltd Borsa (SPRC) Ultime notizie
SciSparc and Clearmind Secure European Patent for Cocaine Addiction Therapy - TipRanks
SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - Stock Titan
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC) - The Globe and Mail
SciSparc Ltd: Weathering Stock Market Storms with 3.17M Market Cap - investchronicle.com
A review of SPRC’s current quarter earnings predictions - uspostnews.com
What's Going On With jeffs' Brands Today? - Benzinga
Jeffs' Brands to Sell Smart Repair Pro Unit, SciSparc Nutraceuticals Stake to Plantify Foods; Shares Jump - marketscreener.com
SciSparc and Clearmind file patent for eating disorder treatment - Investing.com
SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India
SciSparc announces collaboration with Clearmind Medicine - TipRanks
SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times
SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire
Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan
3 Reasons OMI is Risky and 1 Stock to Buy Instead - The Globe and Mail
Thinking Of Selling SciSparc Ltd (NASDAQ: SPRC) Stock? Check This Out First - Stocksregister
SciSparc (NASDAQ:SPRC) Shares Down 6% – Here’s Why - Defense World
SciSparc Extends Deadline for Miza III Ventures Deal - TipRanks
SciSparc Ltd. Extends Merger Agreement with AutoMax Motors - TipRanks
SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 1,435.0% in March - Defense World
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - Louisiana First News
SciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent Application - TipRanks
Is the SciSparc Ltd (NASDAQ:SPRC) stock an investment opportunity? - US Post News
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Extends $2 Million Loan to Support Automax?s Growth Following Automax?s Entry into Direct Import of JAC Electric Vehicles - Marketscreener.com
SciSparc Ltd. Agrees to Sell MitoCareX to N2OFF - TipRanks
SciSparc signs definitive agreement to sell MitoCareX to N2OFF - TipRanks
SciSparc to sell MitoCareX to N2Off for $700,000 - MSN
SciSparc divests MitoCareX stake for $700,000 and stock swa By Investing.com - Investing.com South Africa
SciSparc divests MitoCareX stake for $700,000 and stock swa - Investing.com
SciSparc Ltd. Announces Sale of MitoCareX Shares to N2Off for $700,000 and Stock Exchange Agreement - Nasdaq
SciSparc Signs Definitive Agreement to Sell MitoCareX, - GlobeNewswire
SciSparc's Strategic Exit: How Its MitoCareX Sale Could Deliver $2.3M+ in Value - StockTitan
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
SciSparc Extends $2 Million Loan to Support AutoMax's - GlobeNewswire
SciSparc provides $2 million loan to AutoMax for expansion - Investing.com Australia
SciSparc Enters $4.2M Securities Agreement and Supports AutoMax Expansion with $2M Loan - TipRanks
SciSparc provides $2 million loan to AutoMax for expansion By Investing.com - Investing.com South Africa
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles - The Manila Times
SciSparc extends $2M loan to support AutoMax growth - TipRanks
SciSparc Ltd. Enters $2 Million Loan Agreement with AutoMax Motors to Support Business Expansion - Nasdaq
SciSparc Bets $2M on Electric Vehicle Future with Latest AutoMax Financing - StockTitan
N2OFF to acquire biotech firm MitoCareX in strategic move - Investing.com
Scisparc Ltd Azioni (SPRC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.19%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):